As a prospective target for future studies, it will be important to validate cinnamic acid’s hepatoprotective efficacy across diverse NAFLD paradigms, such as the methionine–choline-deficient diet model or genetically predisposed mouse strains, to ascertain its activity against differing etiologies, and to explore combination regimens pairing CA with established insulin sensitizers or complementary antioxidants in order to assess potential synergistic benefits on lipid metabolism, oxidative stress, and inflammatory signaling. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.